Target Name: IL18
NCBI ID: G3606
Review Report on IL18 Target / Biomarker Content of Review Report on IL18 Target / Biomarker
IL18
Other Name(s): interleukin-1 gamma | IGIF | iboctadekin | IL-18 | IL-1 gamma | interleukin 18 | MGC12320 | IFN-gamma-inducing factor | Interleukin-18 (isoform 1) | Iboctadekin | Interleukin 18, transcript variant 2 | IL1F4 | Interleukin 18, transcript variant 1 | IL18 variant 2 | Interleukin-18 (isoform 2) | Interferon gamma-inducing factor | interleukin 18 (interferon-gamma-inducing factor) | IL18 variant 1 | Interleukin-18 | IL-1g | IL18_HUMAN | Interleukin 18 (interferon-gamma-inducing factor) | Interleukin-18 (IL-18) | Interleukin-1 gamma | Interferon-gamma-inducing factor

IL-18: A Potential Drug Target and Biomarker

IL-18 (Interleukin-1 Gamma) is a protein that plays a crucial role in the immune system and has been identified as a potential drug target for various diseases. IL-18 is a cytokine that is produced by various types of immune cells in the body, including natural killer cells, macrophages, and dendritic cells. It is a key factor in the regulation of inflammation and immune responses, and has been implicated in a wide range of diseases, including cancer, autoimmune disorders, and bacterial infections.

IL-18 has been shown to promote the recruitment and activation of immune cells, including natural killer cells, which are a crucial part of the immune system and are responsible for targeting and destroying infected or mutated cells. It has also been shown to stimulate the production of other immune cells, such as T-cells, which are responsible for cell-mediated immunity. In addition, IL-18 has been shown to play a key role in the regulation of inflammation, as it has been shown to reduce the production of pro-inflammatory cytokines and increase the production of anti-inflammatory cytokines.

Despite the potential benefits of IL-18 as a drug target, there are also several concerns about its use. One of the main concerns is that IL-18 has been shown to promote the growth and survival of various types of cancer cells, which could make it a potential cancer risk. Additionally, the production of IL-18 has been shown to be increased in individuals with certain genetic variations, which could make it a potential biomarker for certain types of cancer.

Despite these concerns, research into IL-18 as a drug target is still in its early stages. While several studies have shown that IL-18 can be a potent drug target, more research is needed to fully understand its effects and potential uses.

One potential way to use IL-18 as a drug target is to block its production or to reduce its levels in the body. This could be done through a variety of methods, including the use of small molecules, antibodies, or other types of therapeutics. For example, researchers have shown that small molecules such as inhibitors of the IL-18 receptor can be effective in blocking its production and reducing its levels in cancer cells. Similarly, antibodies against IL-18 have been shown to be effective in reducing the production of IL-18 in certain types of cancer cells.

Another potential way to use IL-18 as a drug target is to use it as a biomarker. IL-18 has been shown to be produced in response to various types of infections and diseases, and its levels can be used as a marker for the presence of certain diseases. For example, IL-18 has been shown to be produced in response to bacterial infections, and its levels can be used as a marker for the presence of certain bacterial infections. Similarly, IL-18 has been shown to be produced in response to certain types of cancer, and its levels can be used as a marker for the presence of certain types of cancer.

While the potential use of IL-18 as a drug target or biomarker is still in its early stages, it has the potential to be a valuable tool for the treatment of a wide range of diseases. As research continues to progress, it is likely that new uses and applications for IL-18 will be discovered, and its potential as a drug target or biomarker will be further explored.

In conclusion, IL-18 is a protein that plays a crucial role in the immune system and has been identified as a potential drug target for various diseases. While there are concerns about its potential use as a cancer risk, research into its effects and potential uses is still in its early stages. Further research is needed to fully understand its effects and potential uses, and to develop safe and effective treatments for the use of IL-18.

Protein Name: Interleukin 18

Functions: Pro-inflammatory cytokine primarily involved in epithelial barrier repair, polarized T-helper 1 (Th1) cell and natural killer (NK) cell immune responses (PubMed:10653850). Upon binding to IL18R1 and IL18RAP, forms a signaling ternary complex which activates NF-kappa-B, triggering synthesis of inflammatory mediators (PubMed:14528293, PubMed:25500532). Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells and natural killer (NK) cells (PubMed:10653850). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33883744)

The "IL18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

IL18BP | IL18R1 | IL18RAP | IL19 | IL1A | IL1B | IL1F10 | IL1R1 | IL1R2 | IL1RAP | IL1RAPL1 | IL1RAPL2 | IL1RL1 | IL1RL2 | IL1RN | IL2 | IL20 | IL20RA | IL20RB | IL21 | IL21-AS1 | IL21R | IL21R-AS1 | IL22 | IL22RA1 | IL22RA2 | IL23A | IL23R | IL24 | IL25 | IL26 | IL27 | IL27RA | IL2RA | IL2RB | IL2RG | IL3 | IL31 | IL31RA | IL32 | IL33 | IL34 | IL36A | IL36B | IL36G | IL36RN | IL37 | IL3RA | IL4 | IL4I1 | IL4R | IL5 | IL5RA | IL6 | IL6-AS1 | IL6R | IL6R-AS1 | IL6ST | IL6ST-DT | IL6STP1 | IL7 | IL7R | IL9 | IL9R | IL9RP3 | IL9RP4 | ILDR1 | ILDR2 | ILF2 | ILF3 | ILF3-DT | ILK | ILKAP | ILRUN | ILVBL | Imidazoline I2 receptor (I2) | Imidazoline I3 receptor (I3) | Imidazoline receptor | IMMP1L | IMMP2L | IMMT | IMMTP1 | Immunoglobulin A | Immunoglobulin E (IgE) | Immunoglobulin G | Immunoglobulin M | Immunoglobulin-Like Domain Containing Receptor | Immunoproteasome | IMP3 | IMP4 | IMPA1 | IMPA1P1 | IMPA2 | IMPACT | IMPDH1 | IMPDH1P10 | IMPDH1P6 | IMPDH2 | IMPG1 | IMPG2